HL60細胞株是來(lái)自FAB分型中M2型（急性粒細胞白血病部分分化型）患者，而不是M3型（急性早幼粒細胞白血?。┗颊?。這一結論的得出來(lái)自對該患者骨髓細胞的光學(xué)和超微結構的形態(tài)學(xué)分析。該患者骨髓涂片的分析顯示原始粒細胞占37%，早幼粒細胞占44%，中幼粒細胞以及更成熟階段細胞占8%。HL60細胞株缺少急性早幼粒細胞白血病的一些區分特征：過(guò)氧化物酶染色強度沒(méi)有通常的FAB-M3型細胞強；沒(méi)有裂片形式的顆?；駻uer小體；內質(zhì)網(wǎng)不是非常擴大的。細胞遺傳學(xué)檢測顯示在HL60細胞株中沒(méi)有發(fā)現15號或17號染色體結構的異常。HL60細胞株所代表的白血病類(lèi)型是急性粒細胞白血病部分分化型而并非急性早幼粒細胞白血病

相關(guān)文獻：HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood. 1988 Jan;71(1):242-7

abstract:The leukemia from which the human cell line HL-60 was derived was classified in 1976 as acute progranulocytic leukemia (APL), although it was recognized to show a number of atypical features. In the ensuing 10 years, the concept of APL and its integral association with t(15;17) has evolved, and the concept of APL as a morphologically recognizable entity has become embodied in the term French-American-British classification M3 (FAB-M3). It is now recognized that not every case of leukemia with a high proportion of progranulocytes can be classified as FAB-M3. We reviewed the light and ultrastructural morphology of the original diagnostic material from this case, and we report that the leukemia from which HL-60 was derived does not conform to the currently recognized entity of FAB-M3 and is more appropriately classified as an acute myeloblastic leukemia with maturation, FAB-M2.